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portion of patients receiving each drug was calculated using defined daily doses.
Changes in this distribution over time across all 27 Brazilian states were analyzed.
RESULTS: The estimated yearly number of MS patients treated within the BPHS
was 3,569, 4,894, 5,800, and 6,099 from 2006 to 2009. The probability of use of
Glatiramer 20mg increased from 9.5% in 2006 to 20.1% in 2007, maintaining similar
proportions in the following years (20.7% and 21.28%). The lower proportion of
treated patients was observed for Betainterferon 22mcg, with a constant decre-
ment from 2006 (17.26%) to 2009 (11.39%). The other three available Betainterferon
formulations represented stable distribution of 20-25% each across all years with a
slightly greater probability of use of the 30mcg intramuscular formulation (admin-
istered weekly). Between-states differences were also analyzed and revealed im-
portant spatial discrepancies. For instance, the probability of use of Glatiramer in
2009was 32% in Bahia (Northeast Region) and 13% in Santa Catarina (South Region)
and the proportion of MS patients taking Betainterferon 30mcg was 36% in Rio
Grande do Sul (South Region) and 15% in Bahia. CONCLUSIONS: Although a pro-
portional distribution of Glatiramer and Betainterferon formulations is coherent
with the BPHS guideline which stated that their efficacy should be considered
similar, significant between-states discrepancies in terms of treatment patterns
were identified.
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OBJECTIVES: Computerized games challenge players to move quickly and accu-
rately, but result in game-specific scores rather than objective data. Newly devel-
oped AccuTrak software with Wii technology can challenge players to move a
cursor to an on-screen target using hands or feet, but also record data that might
help document coordination deficits in peoplewith disabilities. Our purposewas to
examine the reliability and validity of this method. METHODS: Thirty-six healthy
adults and nine people with multiple sclerosis (MS) used a Wii device to move a
cursor and click on the center of a target appearing on a computer screen. AccuTrak
software provided feedback after each set of 6 trials regarding a) the time from
target appearance to click, and b) distance from the target center. Each hand per-
formed 30 trials; each foot performed 36 trials. Time and distance data were com-
pared left-right and hand-foot, and to self-reported movement accuracy from the
Movement Ability Measure as analyzed using item response theory methods.
RESULTS: Intraclass correlation coefficients (ICCs) time and distance data were
0.66 and 0.90, respectively, between dominant and non-dominant hands; between
hand and foot performances ICCs were 0.70 and 0.94. The correlation between
objective data and logit estimates of self-reported ability to move accurately was
0.53 for time and 0.21 for distance. The time-distance relationship fit a power
trendline with R2 equal to 0.80 for healthy volunteers; volunteers with MS did not
fit the same trendline. CONCLUSIONS: Reliability was better for distance data;
concurrent validity with self-report was better with time data. Construct validity
was supported in the observance of Fitts’ Law with speed-accuracy trade-off in
healthy volunteers; people with MS tended to have increased error even with lon-
ger times. The methodology shows promise for use when investigating coordina-
tion deficits such as those in people with multiple sclerosis.
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OBJECTIVES: Multiple Sclerosis (MS) registries collect patient-level longitudinal
data with the aim of improving our understanding of MS. These databases have
provided extensive studies on the natural progression of MS. The purpose of this
study is to assess how disease progression has been estimated and assess the
consistency in methodology and results. METHODS: The publications of 10 major
MSRegistrywebsiteswere searched, followedupwith keyword searches in Embase
and Pubmed. Population-basednatural history studies ondisease progressionwere
included. Primary and non-primary endpoints, such as Expanded Disability Status
Scale (EDSS) outcomes as a measure of progression, were extracted in addition to
statistical methodologies. We evaluated the consistency between studies in terms
of endpoints and statistical methodology. RESULTS: Our search identified 23 stud-
ies, of which nine met the inclusion criteria. The majority of papers utilized the
Kaplan-Meier Survival technique to estimate time until disease endpoints and Cox
proportional hazard models to determine prognostic factors. Lack of standards in
reporting results prevented a global comparison. The most commonly reported
endpoint was median time to EDSS six for MS or relapsing-remitting MS patients,
enabling comparison between six studies. Values were reported between 11.9 to
27.9 years. Excluding studies prior to 1999, the median time to EDSS six was be-
tween 20-27.9 years. Results reported from the European based Lyon and LORSEP
registries were consistent (20-24 years), while studies in Canada and Germany
showed greater disparity. Common prognostic factors included age and type of MS
at onset. CONCLUSIONS: Lack of international standards for reporting outcomes in
natural history progression hinders comparisons between studies, especially be-
tween the United States and Europe. While there is some consensus between reg-
istries regarding prognostic factors for progression, not all agree. Heterogeneity in
underlying characteristics of the populations, evolution in best supportive care and
access to treatments could all contribute.
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OBJECTIVES: The objective of this analysis was to compare two commonly used
adherence calculations for multiple sclerosis patients prescribed disease modify-
ing drugs (DMDs) in a national managed care population.METHODS: Patients with
pharmacy claims for self-injectable DMDs were selected from 2007-2008 Thomson
MedStat data. Adherence was calculated across all DMDs for 12 months after the
first DMD claim (i.e., index date) using two different adherence calculation meth-
ods. Traditional medication possession ratio (TMPR) was calculated by summing
the days supply from the first to the last prescription and dividing by the time
between the last prescription date plus the days supply on the last prescription and
the first prescription date. The MMPR used the same numerator but divided by the
365 days of the follow-up period. The TMPRwas calculated based on available data
(no eligibility requirements) while MMPR requires continuous eligibility for the
12-month follow-up period. RESULTS: The mean adherence value for TMPR
(n3,405) was 90.5% whereas the mean adherence value for MMPR (n2,145) was
78.0%. Based on TMPR, 82.3% of patients were considered adherent (80%) while
this value decreased to 63.7% for MMPR. CONCLUSIONS: The MPR is often used to
describe patient adherence. This adherence measure, however, can be calculated
using different time periods in the denominator. These results demonstrate the
importance of understanding the adherence calculation method and the popula-
tion in which the measure is generated, and the potential implications to patient
care.
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OBJECTIVES: To seek to identify unknown subgroups of patients who exhibit treat-
ment effects using growth mixture model (GMM) analyses in studies where con-
ventional analysis failed to find overall treatment effects. METHODS: Analyses
were performed on data from two 26-week clinical trials assessing the effects of
D-Cycloserine on cognitive function using the CDR System in patients with Alzhei-
mer’s disease. Both trials contained three dose-ranging treatment groups and one
placebo group. Latent growth model (LGM) analyses explored composite scores of
attention (Power of Attention - PowAtt) and speed of retrieval of information held
in memory (SpeedMem), while GMM analyses were used to identify latent classes
of differential responders. RESULTS:While no overall treatment benefit was iden-
tified, variability in PowAtt and SpeedMem was found suggesting possible subsets
of patients with differential response to treatment. GMM analyses identified two
distinct subsets of patients, one comprising 70% and the other 30% of the trial
sample. The larger subset had low baseline SpeedMem scores compared to the
smaller subset (range: 6 – 8 seconds total response time vs. 16-20 seconds) and
exhibited no change over time. Within the smaller subset, the low/medium dose
and placebo arms showed deterioration in SpeedMem scores of 3.4 to 9 seconds at
26 weeks. The low/medium dose patients showed the greatest deterioration
whereas the high dose patients showed little deterioration at 26 weeks (1.5
seconds). CONCLUSIONS: Original analyses indicated no treatment benefit while
LGMs showed all treatment arms to deteriorate over the trial. The GMMs, however,
indicated a subset of patients on high dose (7% of trial sample) who showed little
deterioration whereas all other treatment arms showed substantial slowing on
memory tests. The GMMs thus have the potential to identify subsets of patients
who may benefit from treatment even when the main trial findings are inconclu-
sive.
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OBJECTIVES: Increased upper airway resistance during sleep, or snoring, is a risk
factor for sleep disordered breathing, and has been implicated in the development
of adverse cardiovascular outcomes as well as components of the metabolic syn-
drome such as obesity, insulin resistance, and dyslipidemia. Despite increasing
awareness of the health risks associated with frequent snoring, many patients
remain untreated andmay be unaware of snoring, especially if living alone. For this
reason, we examined whether data available in routinely administered physiolog-
ical and laboratory exams would prove useful in developing predictive models of
habitual snoring. METHODS: A total of 10,482 respondents from the 2005-2008
National Health andNutrition Examination Survey (NHANES), for which individual
sleep survey, demographic, and physiological data were available, and who were
not previously diagnosedwith sleep apnea,were classified as frequent snorers (5 or
more nights per week, n 3222), or control (n7260). Sample data were partitioned
into training (45%), validation (35%), and testing (30%) data sets using an equal
stratification criterion for development of logistic regression, decision tree, and
neural network predictive models using SAS Enterprise Miner. RESULTS: All three
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